✦ LIBER ✦

Evaluation of glycosphingolipid clearance in patients with Fabry disease treated with agalsidase alfa who switched to agalsidase beta (the INFORM study)

✍ Scribed by Barranger, John A.; Gambello, Michael J.; Goker-Alpan, Ozlem; Maegawa, Gustavo H.B.; Nedd, Khan J.; Gruskin, Daniel J.; Blankstein, Larry; Weinreb, Neal J.

Book ID: 122311733
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 48 KB
Volume: 111
Category: Article
ISSN: 1096-7192
DOI: 10.1016/j.ymgme.2013.12.037

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical observations on enzyme replacem

Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa

✍ Lin, Hsiang-Yu; Huang, Yu-Hsiu; Liao, Hsuan-Chieh; Liu, Hao-Chuan; Hsu, Ting-Ron 📂 Article 📅 2014 🏛 Elsevier Science 🌐 Chinese ⚖ 414 KB

Prospective Results of Switching Enzyme

Prospective Results of Switching Enzyme Replacement Therapy from Agalsidase beta to Agalsidase alfa in the Canadian Fabry Disease Initiative Study

✍ Michael West; Daniel Bichet; Robin Casey; Joe Clarke; Sandra Sirrs; Gordon Flowe 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 64 KB

An open-label, switchover trial to asses

An open-label, switchover trial to assess the safety and efficacy of agalsidase beta in patients with Fabry disease treated with agalsidase alfa enzyme replacement therapy

✍ Richards, Sarah; Laney, Dawn; Pervaiz, Muhammad A.; Shankar, Suma 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 62 KB

[JIMD Reports] JIMD Reports - Case and R

[JIMD Reports] JIMD Reports - Case and Research Reports, 2012/6 Volume 9 || Effects of Switching from Agalsidase Beta to Agalsidase Alfa in 10 Patients with Anderson-Fabry Disease

✍ Zschocke, Johannes; Gibson, K Michael; Brown, Garry; Morava, Eva; Peters, Verena 📂 Article 📅 2012 🏛 Springer Berlin Heidelberg ⚖ 163 KB

Female Fabry disease: significant improv

Female Fabry disease: significant improvement of Fabry disease-related gastrointestinal symptoms in a large cohort of female patients treated with agalsidase beta: data from the Fabry Registry

✍ Wilcox, William; Feldt-Rasmussen, Ulla; Martins, Ana Maria; Ortiz, Alberto; Weid 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 74 KB

A randomized, open-label study to compar

A randomized, open-label study to compare the efficacy and safety of AT1001 and enzyme replacement therapy (ERT) in patients with Fabry disease and AT1001-responsive GLA mutations, who were previously treated with ERT

✍ Mathews Adera; Allison Gladden; Pol Boudes 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 60 KB